Chronic Total Occlusion

Placidus Medical has developed together with the Jet Propulsion Laboratories (JPL NASA), a patented game-changing piezoelectric actuated total occlusion drilling device that consists of combined vibratory piezoelectric actuator and a rotary motor. The disclosed device is equipped with features and capacities that minimize potential thermal or physical damage and produces minute size fragments. A vibratory actuator drives a drilling-wire that is inserted via guiding-sleeve, such as the ones used in medical procedures for treating occlusions. The drilling-wire is used to penetrate chronic plaques as part of the procedure of treating plagued arteries. It is designed and equipped with features that minimize potential thermal or physical damage to artery walls and its designed to produce minute size fragments.

Chronic Total Occlusion

According to World Health Organization, Chronic Vascular Disease is world number one killer. 17.5 million people die each year from CVD's an estimated 31% of all deaths worldwide.
Chronic Total Occlusion (CTO) of the arteries remains a huge challenge without a real solution. CTO is a complete blockage of the artery and occurs in 20% of patients who undergo diagnostic cardiac catheterization. This figure is higher among individuals with multi vessel coronary disease. 
 
The capability to drill an occlusion is critically needed in order to provide a path for other medical means of expanding and possibly removing the rest of the occlusion.
The major catheterization obstacle is crossing an occlusion with a guidewire. As soon as the guidewire crosses the occlusion, it can be treated with balloon angioplasty and stent or (if heavily occluded) with rotational atherectomy and stent. 

Calcified Plaque are very difficult to cross even with the most hard and slippery wire. Many times the wire penetrates the vessel wall instead of crossing the center of the plaque over to the distal vessel lumen. Failure to position the wire at the center of the vessel beyond the occlusion, leading to failure of the procedure and many require vascular surgery.
 
The PlacidWire
 
Our patented technology has been developed for over twenty years by JPL and NASA and is being developed by Placidus, JPL and NASA for several years to bring the cardiovascular market a revolutionary CTO crossing device.
We have successfully tested our prototype several times on human CTO's crossing total occlusions in seconds with no thermal or physical damage and minute size fragments production.
 
For more information visit Placidus Medical website at
www.placidusmed.com
 
 
 
Chronic Total Occlusion